希腊研究科维德-19 并发症预防中的秋水仙碱作用（GRECCO-19 研究）：原理和研究设计。
The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design.
机构信息
Medical School, National & Kapodistrian University of Athens, Athens, Greece.
Medical School, National & Kapodistrian University of Athens, Athens, Greece.
出版信息
Hellenic J Cardiol. 2020 Jan-Feb;61(1):42-45. doi: 10.1016/j.hjc.2020.03.002. Epub 2020 Apr 3.
OBJECTIVE
Colchicine has been utilized safely in a variety of cardiovascular clinical conditions. Among its potential mechanisms of action is the non-selective inhibition of NLRP3 inflammasome which is thought to be a major pathophysiologic component in the clinical course of patients with COVID-19. GRECCO-19 will be a prospective, randomized, open-labeled, controlled study to assess the effects of colchicine in COVID-19 complications prevention.
METHODS
Patients with laboratory confirmed SARS-CoV-2 infection (under RT PCR) and clinical picture that involves temperature >37.5 oC and at least two out of the: i. sustained coughing, ii. sustained throat pain, iii. Anosmia and/or ageusia, iv. fatigue/tiredness, v. PaO2<95 mmHg will be included. Patients will be randomised (1:1) in colchicine or control group.
RESULTS
Trial results will be disseminated through peer-reviewed publications and conference presentations.
CONCLUSION
GRECCO-19 trial aims to identify whether colchicine may positively intervene in the clinical course of COVID-19. (ClinicalTrials.gov Identifier: NCT04326790).
目的
秋水仙碱已在多种心血管临床情况下安全使用。其潜在作用机制之一是非选择性抑制 NLRP3 炎性体，这被认为是 COVID-19 患者临床病程中的主要病理生理成分。GRECCO-19 将是一项前瞻性、随机、开放标签、对照研究，旨在评估秋水仙碱在 COVID-19 并发症预防中的作用。
方法
将纳入经实验室确证的 SARS-CoV-2 感染（RT-PCR 检测）且临床症状涉及体温 >37.5°C 且至少满足以下两种情况的患者：i. 持续咳嗽，ii. 持续咽喉疼痛，iii. 嗅觉丧失和/或味觉丧失，iv. 疲劳/乏力，v. PaO2<95 mmHg。患者将按照 1:1 的比例随机分配到秋水仙碱组或对照组。
结果
试验结果将通过同行评审的出版物和会议报告进行传播。
结论
GRECCO-19 试验旨在确定秋水仙碱是否可能对 COVID-19 的临床病程产生积极影响。（临床试验标识符：NCT04326790）。
Zotero 插件